Program
HRS-4508
A development code. Also written as “HRS-4508 tablet”, “HRS-6209 in Combination HRS-4508 and letrozole” and “HRS-4508+ Capecitabine”.
In Jiangsu HengRui Medicine's pipeline, HER2
. Its studies are mostly in Breast Neoplasms · Lung Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 55 open or running | phase 2since Aug 1, 2024 | Aug 1, 2024 | Sep 2027phase 2 · NCT07003321 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-4508
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 1, 2024First study: phase 2 study in Breast NeoplasmsFirst studyNCT06555068 · 528 planned · China
- Sep 12, 2024Phase 1 study in Advanced Solid TumorsNCT06598735 · 290 planned · China
- May 26, 2025Phase 2 study in Solid TumorNCT07003321 · 120 planned · China
- Aug 17, 2025Phase 2 study in Solid TumorNCT07140393 · 120 planned · China
- Nov 14, 2025Phase 2 study in Lung NeoplasmsNCT07232849 · 100 planned · China
Ahead
- Sep 2027Primary completion: phase 2 study in Solid TumorNCT07003321
- Oct 2027Primary completion: phase 2 study in Solid TumorNCT07140393
- Dec 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07232849
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
TargetBeta
“HER2”the company's pipeline, read by Claude · source
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07232849Lung Neoplasms · China | 2 | Recruiting | Dec 2027 | 100 |
| NCT07140393Solid Tumor · China | 2 | Recruiting | Oct 2027 | 120 |
| NCT07003321Solid Tumor · China | 2 | Recruiting | Sep 2027 | 120 |
| NCT06598735Advanced Solid Tumors · China | 1 | Recruiting | Dec 30, 2027 | 290 |
| NCT06555068Breast Neoplasms · China | 2 | Recruiting | Dec 2027 | 528 |
How it is read
Names in the registry
- “HRS-4508 tablet”, 2 entries
- “HRS-6209 in Combination HRS-4508 and letrozole”, 1 entry
- “HRS-4508”, 1 entry
- “HRS-4508+ Capecitabine”, 1 entry
- “HRS-4508+ Trastuzumab”, 1 entry
Codes read as this program: HRS4508.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.